Literature DB >> 9059349

The value of immunohistochemistry on paraffin wax embedded tissue sections in the differentiation of small lymphocytic and mantle cell lymphomas.

N Singh1, D H Wright.   

Abstract

AIMS: To determine whether immunohistochemistry applied to paraffin wax embedded biopsy tissue can be used to distinguish between B-small lymphocytic lymphoma (B-SLL) and mantle cell lymphoma (MCL).
METHODS: Formalin fixed, paraffin wax embedded tissue blocks of 12 cases of B-SLL and 12 cases of MCL were retrieved from the files of the Department of Pathology, Southampton University Hospitals Trust. Following antigen retrieval, where appropriate, sections were stained for CD3, CD5, CD20, CD23, CD43, Cyclin D, PGP9.5, and MIB1 using a streptavidin-biotin complex technique.
RESULTS: CD20 stained the neoplastic cells of B-SLL and MCL, and CD3 labelled the reactive T cells in these tumours. In B-SLL, the T cells were generally dispersed among the tumour cells, whereas in MCL they often formed bands around tumour cell nodules. CD5 could be detected on T cells, following antigen retrieval. The level of expression on B cells of B-SLL and MCL was generally too low to allow detection in paraffin wax embedded tissues. CD23 stained B-SLL but not MCL. However, it could be detected in only five of the 12 cases of B-SLL. CD43 could be detected in most cases of B-SLL and MCL. It is not, therefore, of value in distinguishing between these tumours. It will, however, help in the differentiation of B-SLL and MCL from other low grade B cell lymphomas, such as follicle centre cell and marginal zone lymphomas. Cyclin D was expressed in all of the MCL but in none of the B-SLL. PGP9.5 showed reactivity in most cases of MCL and much weaker reactivity in B-SLL. The proliferation indexes of MCL were generally higher than those of B-SLL, as measured by MIB1 labelling. Both tumours, however, showed a wide range of values and considerable overlap.
CONCLUSION: Staining for Cyclin D is the most reliable immunohistochemical mean of differentiating between B-SLL an MCL. High levels of PGP9.5, expressed in MCL, may be related to the degradation of Cyclin D by the ubiquitin pathway.

Entities:  

Mesh:

Year:  1997        PMID: 9059349      PMCID: PMC499705          DOI: 10.1136/jcp.50.1.16

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  29 in total

1.  The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase.

Authors:  K D Wilkinson; K M Lee; S Deshpande; P Duerksen-Hughes; J M Boss; J Pohl
Journal:  Science       Date:  1989-11-03       Impact factor: 47.728

2.  Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations.

Authors:  P Lardelli; M A Bookman; J Sundeen; D L Longo; E S Jaffe
Journal:  Am J Surg Pathol       Date:  1990-08       Impact factor: 6.394

3.  Immunologic characterization of human malignant lymphomas.

Authors:  R J Lukes; R D Collins
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

4.  Lymphocytic lymphoma of intermediate differentiation--mantle zone lymphoma: a distinct subtype of B-cell lymphoma.

Authors:  E S Jaffe; M A Bookman; D L Longo
Journal:  Hum Pathol       Date:  1987-09       Impact factor: 3.466

5.  Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma.

Authors:  D D Weisenburger; H Kim; H Rappaport
Journal:  Cancer       Date:  1982-04-01       Impact factor: 6.860

6.  Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/cyclin D1 gene.

Authors:  S H Swerdlow; W I Yang; L R Zukerberg; N L Harris; A Arnold; M E Williams
Journal:  Hum Pathol       Date:  1995-09       Impact factor: 3.466

7.  Intermediate lymphocytic lymphoma: immunophenotypic and cytogenetic findings.

Authors:  D D Weisenburger; W G Sanger; J O Armitage; D T Purtilo
Journal:  Blood       Date:  1987-06       Impact factor: 22.113

8.  Intermediate lymphocytic lymphoma: an immunohistologic study with comparison to other lymphocytic lymphomas.

Authors:  D D Weisenburger; J Linder; D T Daley; J O Armitage
Journal:  Hum Pathol       Date:  1987-08       Impact factor: 3.466

9.  Intermediate lymphocytic lymphoma: an immunophenotypic study with comparison to small lymphocytic lymphoma and diffuse small cleaved cell lymphoma.

Authors:  J G Strickler; L J Medeiros; C M Copenhaver; L M Weiss; R A Warnke
Journal:  Hum Pathol       Date:  1988-05       Impact factor: 3.466

10.  The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma.

Authors:  M N Kilo; D M Dorfman
Journal:  Am J Clin Pathol       Date:  1996-04       Impact factor: 2.493

View more
  4 in total

1.  "In situ-like" mantle cell lymphoma: a report of two cases.

Authors:  P Richard; J Vassallo; S Valmary; R Missoury; G Delsol; P Brousset
Journal:  J Clin Pathol       Date:  2006-09       Impact factor: 3.411

2.  Growth pattern and distribution of follicular dendritic cells in mantle cell lymphoma: a clinicopathological study of 96 patients.

Authors:  Carsten Schrader; Peter Meusers; Günter Brittinger; Dirk Janssen; Afshin Teymoortash; Jens U Siebmann; Reza Parwaresch; Markus Tiemann
Journal:  Virchows Arch       Date:  2005-08-17       Impact factor: 4.064

3.  Mantle cell lymphoma: improved diagnostics using a combined approach of immunohistochemistry and identification of t(11;14)(q13;q32) by polymerase chain reaction and fluorescence in situ hybridization.

Authors:  Roman Kodet; Marcela Mrhalová; Lenka Krsková; Jan Soukup; Vít Campr; Tomás Neskudla; Peter Szépe; Lukás Plank
Journal:  Virchows Arch       Date:  2003-05-01       Impact factor: 4.064

4.  CD5-positive diffuse large B cell lymphoma arising from a CD5-positive follicular lymphoma.

Authors:  José Vassallo; Marina Bousquet; Cathy Quelen; Talal Al Saati; Georges Delsol; Pierre Brousset
Journal:  J Clin Pathol       Date:  2007-05       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.